Clinical Trial Update: Preventive Application of GnRH Antagonist on Early OHSS [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining preventive use of a GnRH antagonist to reduce early ovarian hyperstimulation syndrome; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• Aspirin (Aspirin)
• GnRH antagonist (unspecified)
• Pigment Epithelium Derived Factor (pigment epithelium-derived factor)
• Vascular Endothelial Growth Factor (vascular endothelial growth factor)

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Ovarian Hyperstimulation Syndrome, GnRH Antagonist | Phase 4 | Status: UNKNOWN